NASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.32 +0.07 (+5.60%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$1.33 +0.01 (+0.76%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biomea Fusion Stock (NASDAQ:BMEA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.25▼$1.3450-Day Range$1.17▼$2.0352-Week Range$0.87▼$2.24Volume834,943 shsAverage Volume2.05 million shsMarket Capitalization$95.67 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets. Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes. Biomea’s pipeline and development programs are subject to clinical testing and regulatory review, and its investigational products have not been approved for commercial use. Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion became a publicly traded company in 2021. The company’s operations are primarily focused on research, clinical development and collaboration with medical and regulatory organizations in support of its drug candidates. Thomas Butler serves as Biomea Fusion’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 43% of companies evaluated by MarketBeat, and ranked 643rd out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBiomea Fusion has a consensus price target of $9.00, representing about 581.8% upside from its current price of $1.32.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Biomea Fusion are expected to decrease in the coming year, from ($0.73) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.40% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 6.44.Change versus previous monthShort interest in Biomea Fusion has recently increased by 10.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.30 News SentimentBiomea Fusion has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows7 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders10.60% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMEA Stock News HeadlinesBiomea Fusion (NASDAQ:BMEA) Stock Rating Raised to "Hold" at Wall Street ZenOctober 5 at 1:06 AM | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsSeptember 28, 2026 | americanbankingnews.comOminous New Day in America (Get Ready for it)A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S&L collapse and Black Monday crash, and the 2000s dot-com bust and Lehman Brothers collapse - says a major shift is coming to how Americans bank, work and insure themselves. The New York Times has credited him as the first to spot looming dangers, and he has testified before Congress on past financial crises.October 8 at 1:00 AM | Weiss Ratings (Ad)Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway PressureSeptember 24, 2026 | seekingalpha.comBiomea Fusion Shares Fall After Terminating Proposed Public OfferingSeptember 24, 2026 | finance.yahoo.comBiomea Fusion Terminates Planned Securities Offering; Shares SlideSeptember 24, 2026 | rttnews.comBiomea slips after halting stock offering, delaying trial readoutSeptember 23, 2026 | seekingalpha.comBiomea Fusion Launches Public Offering; Stock DownSeptember 23, 2026 | rttnews.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $1.24 at the beginning of 2026. Since then, BMEA stock has increased by 6.5% and is now trading at $1.32. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.10. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $144 million in an initial public offering on Thursday, April 15th 2021. The company issued 9,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/05/2026Today10/08/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, BMEA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Price Target for Biomea Fusion$9.00 High Price Target$12.00 Low Price Target$7.00 Potential Upside/Downside+581.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-253.73% Return on Assets-97.91% Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio3.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book3.14Miscellaneous Outstanding Shares72,480,000Free Float64,801,000Market Cap$95.67 million OptionableOptionable Beta-0.28 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BMEA) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhat Could Change After November 3rd?Democrats are favored to take the House on November 3rd, needing just five seats to flip the chamber. The last...USA Capital Gold | Sponsored“Whoever wins AI, wins”Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredLook at Elon’s face after meeting with ChinaElon Musk recently met with Chinese President Xi Jinping, and a former Wall Street Journal Personal Finance Ex...International Living | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
